Lawrence Guiheen

Lawrence Guiheen

Director/Board Member at ADMA BIOLOGICS, INC.

Net worth: 1 M $ as of 31/05/2026

75 year
Health Technology
Commercial Services
Consumer Services

Profile

Lawrence P.
Guiheen
is an Independent Director at ADMA Biologics, Inc. since 2012 and a Director at Kedrion Biopharma, Inc. since 2019.
Former roles include Chief Executive Officer at Wellmond Therapeutics from 2019 to 2022, Executive Vice President at Wellstat Management Co. LLC from 2019 to 2022, General Manager-Global Hemophilia Franchise at Baxter Healthcare Corp.
from 2010 to 2011, President-BioPharmaceuticals at Baxter BioScience Corp.
from 2010 to 2011, Principal at Guiheen & Associates LLC from 2011 to 2013, Chairman at Plasma Protein Therapeutics Association, and Director at California Healthcare Institute.
Education includes undergraduate studies at Rutgers State University of New Jersey.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
31/03/2026 175,820 ( 0.08% ) 1 M $ 31/05/2026

Lawrence Guiheen active positions

CompaniesPositionStart
ADMA BIOLOGICS, INC. Director/Board Member 24/07/2012
Director/Board Member 01/11/2019

Former positions of Lawrence Guiheen

CompaniesPositionEnd
Wellmond Therapeutics
Chief Executive Officer 01/02/2022
Corporate Officer/Principal 01/02/2022
Guiheen & Associates LLC
Corporate Officer/Principal 01/07/2013
Corporate Officer/Principal -
Corporate Officer/Principal 01/07/2011
See the detail of Lawrence Guiheen's experience

Training of Lawrence Guiheen

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

72

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Health Technology

Health Technology

Commercial Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Guiheen & Associates LLC

Health Services

Wellmond Therapeutics

  1. Stock Market
  2. Insiders
  3. Lawrence Guiheen
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!